Search results for "AEM"

showing 10 items of 1006 documents

Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study

2002

A questionnaire-based retrospective clinical and immunological survey was conducted in 73 males with a definite diagnosis of X-linked agammaglobulinemia based on BTK sequence analysis. Forty-four were sporadic and 29 familial cases. At December 2000, the patients' ages ranged from 2 to 33 years; mean age at diagnosis and mean duration of follow-up were 3.5 and 10 years respectively. After the mid-1980s all but 2 were on intravenous immunoglobulin (IVIG) substitution therapy, with residual IgG >500 mg/dl in 94% of the patients at the time of enrollment. Respiratory infections were the most frequent manifestation both prior to diagnosis and over follow-up. Chronic lung disease (CLD) was prese…

Lung DiseasesAdultMalePediatricsmedicine.medical_specialtyGenetic Linkage; Agammaglobulinemia; Humans; Infant Newborn; Protein-Tyrosine Kinases; Child; Child Preschool; X Chromosome; Immunoglobulins Intravenous; Lung Diseases; Adult; Cohort Studies; Chronic Disease; Follow-Up Studies; Adolescent; Mutation; Maleclinical featuresX ChromosomeX-linked agammaglobulinemiaAdolescentGenetic LinkageImmunologyX-linked agammaglobulinemiaImmunoglobulinsX-linked agammaglobulinemia; infections; intravenous immunoglobulin; BTK mutationSepsisCohort StudiesAgammaglobulinemiaImmunopathologyintravenous immunoglobulinEpidemiologymedicineAgammaglobulinaemia Tyrosine KinaseImmunology and AllergyHumansinfectionsChildPreschoolSettore MED/38 - Pediatria Generale e SpecialisticaBTK mutationsbusiness.industryChronic sinusitisInfant NewbornMeningoencephalitisImmunoglobulins IntravenousInfantProtein-Tyrosine Kinasesmedicine.diseaseNewbornBTK mutationagammaglobulinemia; clinical features; BTK mutationsChild PreschoolChronic DiseaseMutationbusinessIntravenousMeningitisCohort studyFollow-Up Studies
researchProduct

A Multicentre Pilot Study of a Two-Tier Newborn Sickle Cell Disease Screening Procedure with a First Tier Based on a Fully Automated MALDI-TOF MS Pla…

2019

The reference methods used for sickle cell disease (SCD) screening usually include two analytical steps: a first tier for differentiating haemoglobin S (HbS) heterozygotes, HbS homozygotes and β-thalassemia from other samples, and a confirmatory second tier. Here, we evaluated a first-tier approach based on a fully automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) platform with automated sample processing, a laboratory information management system and NeoSickle® software for automatic data interpretation. A total of 6701 samples (with high proportions of phenotypes homozygous (FS) or heterozygous (FAS) for the inherited genes for sickle h…

MALDI-TOFPediatricsmedicine.medical_specialtythalassemia[SDV]Life Sciences [q-bio]Sample (statistics)01 natural sciencesArticle03 medical and health sciencesImmunology and Microbiology (miscellaneous)preventionmedicineDisease Screening Procedure030304 developmental biologymass spectrometry0303 health sciencesNewborn screeningbusiness.industryMALDI-TOF; sickle cell disease; newborn screening; mass spectrometry; thalassemia; preventionnewborn screening010401 analytical chemistrylcsh:RJ1-570Obstetrics and GynecologyData interpretationlcsh:Pediatrics0104 chemical sciencesMatrix-assisted laser desorption/ionizationFully automatedSickle haemoglobinPediatrics Perinatology and Child Healthsickle cell diseaseSample collectionbusinessInternational Journal of Neonatal Screening
researchProduct

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

2011

Chemotherapy remains a commonly used therapeutic approach for many cancers. Indeed chemotherapy is relatively effective for treatment of certain cancers and it may be the only therapy (besides radiotherapy) that is appropriate for certain cancers. However, a common problem with chemotherapy is the development of drug resistance. Many studies on the mechanisms of drug resistance concentrated on the expression of membrane transporters and how they could be aberrantly regulated in drug resistant cells. Attempts were made to isolate specific inhibitors which could be used to treat drug resistant patients. Unfortunately most of these drug transporter inhibitors have not proven effective for ther…

MAPK/ERK pathwayPTENTumor suppressor genekinase inhibitorPhysiologymedicine.medical_treatmentClinical Biochemistrygrowth factor receptorAntineoplastic AgentsDrug resistancePharmacologyBiologyTargeted therapy03 medical and health sciencesMicePhosphatidylinositol 3-Kinases0302 clinical medicineGrowth factor receptormedicinePTENAnimalsHumansExtracellular Signal-Regulated MAP KinasesProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesTOR Serine-Threonine KinasesPTEN PhosphohydrolaseCell BiologyMAP Kinase Kinase Kinases3. Good healthErbB ReceptorsDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationCancer researchbiology.proteinraf KinasesProto-Oncogene Proteins c-aktDrug resistance therapeutic sensitivity targeted therapy RAF ERKACUTE MYELOID LEUKAEMIASignal TransductionJournal of cellular physiology
researchProduct

Whole-Body MRI and 18F-FDG-PET-CT for Lymphoma Staging: Comparison of Patient Experience

2015

Aims and objectives Methods and materials Results Conclusion Personal information References

MRI Lymphomagenetic structuresLymphomaNuclear medicinePET-CTSettore MED/36 - Diagnostica Per Immagini E RadioterapiaDiagnostic procedureLymph nodesHaematologic diseasesHaematologicMR-Diffusion/Perfusion
researchProduct

A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages

2013

AbstractThe differentiation of human peripheral blood monocytes into macrophages can be reproduced ex vivo by culturing the cells in the presence of colony-stimulating factor 1 (CSF1). Using microarray profiling to explore the role of microRNAs (miRNAs), we identified a dramatic decrease in the expression of the hematopoietic specific miR-142-3p. Up- and down-regulation of this miRNA in primary human monocytes altered CSF1-induced differentiation of monocytes, as demonstrated by changes in the expression of the cell surface markers CD16 and CD163. One of the genes whose expression is repressed by miR-142-3p encodes the transcription factor Early Growth Response 2 (Egr2). In turn, Egr2 assoc…

Macrophage colony-stimulating factorAntigens Differentiation MyelomonocyticDown-RegulationChronic myelomonocytic leukemiaReceptors Cell SurfaceCD16BiologyGPI-Linked ProteinsMonocyte–macrophage differentiationMonocytesChronic myelomonocytic leukemiaAntigens CDCell Line TumorMiR-142-3pmedicineHumansTranscription factorMolecular BiologyEarly Growth Response Protein 2Early Growth Response Protein 1Cluster of differentiationMolecular circuitryMacrophage Colony-Stimulating FactorMacrophagesReceptors IgGCell DifferentiationLeukemia Myelomonocytic ChronicCell Biologymedicine.diseaseUp-RegulationRepressor ProteinsMicroRNAsHaematopoiesisMonocyte differentiationCancer researchEgr2K562 CellsK562 cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia.

2010

Abstract Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder that occurs in elderly patients. One of the main diagnostic criteria is the accumulation of heterogeneous monocytes in the peripheral blood. We further explored this cellular heterogeneity and observed that part of the leukemic clone in the peripheral blood was made of immature dysplastic granulocytes with a CD14−/CD24+ phenotype. The proteome profile of these cells is dramatically distinct from that of CD14+/CD24− monocytes from CMML patients or healthy donors. More specifically, CD14−/CD24+ CMML cells synthesize and secrete large amounts of alpha-defensin 1-3 (HNP1-3). Recombinant HNPs inhibit macrophage co…

Macrophage colony-stimulating factoralpha-DefensinsCD14Cellular differentiationImmunologyLipopolysaccharide ReceptorsChronic myelomonocytic leukemiaUridine TriphosphateBiologyGranulocyteBiochemistryMonocytesUridine DiphosphatemedicineMacrophageHumansReceptors Purinergic P2MonocyteMacrophage Colony-Stimulating FactorMacrophagesCD24 AntigenCell DifferentiationLeukemia Myelomonocytic ChronicCell BiologyHematologymedicine.diseaseHaematopoiesismedicine.anatomical_structureCancer researchCytokinesGranulocytesBlood
researchProduct

Tumor necrosis factor (TNF)-alpha but not TNF-beta induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes

1987

Abstract Tumor necrosis factor (TNF)-alpha has been identified as a major inducer of colony stimulating factor (CSF)-secretion by human vascular endothelial cells and fibroblasts. In the present study we assessed the capacity of TNFs to induce release of CSF-1 from highly purified peripheral blood monocyte preparations. Whereas monocytes do not accumulate CSF-1 messenger (m)RNA constitutively and consequently do not produce CSF-1 protein, CSF-1 mRNA and protein secretion became detectable, when monocytes were cultured in the presence of TNF-alpha, that was synergistically enhanced by interferon-gamma (IFN-gamma). However, under identical experimental conditions TNF-beta failed to induce mon…

Macrophage colony-stimulating factormedicine.medical_specialtyT-LymphocytesImmunologyIn Vitro TechniquesBiologyBiochemistryMonocytesColony-Forming Units AssayColony-Stimulating FactorsInternal medicinemedicineHumansSecretionLeukapheresisMessenger RNATumor Necrosis Factor-alphaMonocyteCell BiologyHematologyMacrophage ActivationColony-stimulating factorMolecular biologyHaematopoiesisEndocrinologySecretory proteinmedicine.anatomical_structureTumor necrosis factor alphaBlood
researchProduct

Inulin-iron complexes: a potential treatment of iron deficiency anaemia.

2007

The aim of this work was that to synthesize macromolecular derivatives based on inulin able to complex iron and useful in the treatment of iron deficiency anaemia. Carboxylated or thiolated/carboxylated inulin derivatives were obtained by single or double step reactions, respectively. The first one was obtained by reaction of inulin (INU) with succinic anhydride (SA) alone obtaining INU-SA derivative; the second one was obtained by the reaction of INU with succinic anhydride and subsequent reaction of INU-SA with cysteine; both derivatives were treated with ferric chloride in order to obtain the INU-SA-Fe(III) and INU-SA-Cys-Fe(III) complexes. Both complexes showed an excellent biodegradabi…

Magnetic Resonance SpectroscopyIronInulinPharmaceutical Sciencechemistry.chemical_compoundSpectroscopy Fourier Transform InfraredmedicineMucoadhesionOrganic chemistryHumansInulinaseChromatography High Pressure LiquidAnemia Iron-DeficiencyPolyacrylic acidSuccinic anhydrideInulinInulin iron anaemiaGeneral MedicineIron deficiencymedicine.diseasechemistryIron-deficiency anemiaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFerricSpectrophotometry UltravioletBiotechnologyNuclear chemistrymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Fluoropolymer Based on a Polyaspartamide containing 1,2,4-Oxadiazole Units: A Potential Artificial Oxygen (O2) Carrier

2007

Abstract In this preliminary work we have prepared a fluorinated polymer capable of solubilizing an appreciable amount of O(2) and, at the same time, maintaining a higher water solubility than perfluoroalkanes investigated as injectable O(2) carriers. In particular, we describe the synthesis and characterization of a new macromolecular conjugate obtained by derivatization of alpha,beta-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) with 5-pentafluorophenyl-3-perfluoroheptyl-1,2,4-oxadiazole, called PHEA-F. This new water soluble fluoropolymer was prepared in high yield using a simple procedure. It was characterized by FT-IR and UV-vis spectrophotometry, (19)F-NMR and SEC measurements. O(2) so…

Magnetic Resonance SpectroscopyPolymers and PlasticsBiocompatibilityMacromolecular SubstancesOxadiazoleBioengineeringBiomaterialschemistry.chemical_compoundSpectroscopy Fourier Transform InfraredMaterials ChemistryOrganic chemistrySolubilityDerivatizationAqueous solutionMolecular StructureTemperatureHaemolysisOxygenFluorocarbon PolymerschemistryFluoropolymerSpectrophotometry UltravioletPeptidesBiotechnologyConjugateNuclear chemistryMacromolecular Bioscience
researchProduct

Two New Glycosides from Astragalus caprinus

2001

A new glycoside of flavonol (1) and a new glycoside of a cycloartane-type triterpene (2) were isolated from the leaves and the roots of Astragalus caprinus, respectively. Their structures were elucidated in turn by spectroscopic data interpretation as 3-O-[[beta-D-xylopyranosyl(1-->3)-alpha-L-rhamnopyranosyl(1-->6)][beta-D-apiofuranosyl(1-->2)]]-beta-D-galactopyranosyl kaempferol (1) and 3-O-(beta-D-xylopyranosyl)-24-O-(beta-D-glucopyranosyl)-20,25-epoxycycloartane-3beta,6alpha,16beta,24alpha-tetrol (2).

Magnetic Resonance SpectroscopyTunisiaSpectrophotometry InfraredStereochemistryFlavonoidSaponinPharmaceutical ScienceSpectrometry Mass Fast Atom BombardmentPharmacognosyPlant RootsAnalytical Chemistrychemistry.chemical_compoundTriterpeneDrug DiscoveryTetrasaccharideGlycosidesKaempferolsFlavonoidsPharmacologychemistry.chemical_classificationPlants MedicinalHydrolysisOrganic ChemistryGlycosideSaponinsTriterpenesTerpenoidPlant LeavesComplementary and alternative medicinechemistryMolecular MedicineSpectrophotometry UltravioletKaempferolJournal of Natural Products
researchProduct